FDA approves Eli Lilly's once-weekly insulin for Type 2 diabetes

Eli Lilly received FDA approval for Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes. Backed by the QWINT Phase 3 program involving over 3,400 patients, it matched daily insulin in blood sugar control. This is Onswik's fourth global approval and is expected to launch in US in the coming months.